Hostname: page-component-586b7cd67f-t7fkt Total loading time: 0 Render date: 2024-11-22T07:31:43.086Z Has data issue: false hasContentIssue false
  • English
  • Français

The Involvement of Serotonin in Psychiatric Disorders and Behaviour

Published online by Cambridge University Press:  06 August 2018

Juan J. López-Ibor Jr
Juan J. López-Ibor Jr*
Affiliation:
University of Alcalá de Henares and Ramón y Cajal Hospital, Madrid, Spain
*
Correspondence: Av. Neuva Zelanda 44, E-28035, Madrid, Spain
Get access Rights & Permissions [Opens in a new window]

Extract

There is evidence that serotonin (5-HT) is involved both in a wide range of psychiatric conditions and in specific behaviours which, in themselves, cannot be considered pathological. Besides the affective disorders (both depressive and manic, and both in full-blown episodes and during the intervals between these, which are seen as vulnerability to relapse) several other conditions need to be considered (Table I). There are also claims that serotonin metabolites or structurally related substances are involved, in their role as false neurotransmitters, in delusions and psychedelic phenomena, as in the case of LSD (Mantegazzini, 1960) or 5-hydroxytryptolines in delusions related to alcoholism (Davis et al, 1967).

This wide range of conditions raises the questions of how specific is the involvement of serotonin, and of what artifacts are present in attempts to investigate its actions. Page, who isolated 5-HT in 1948, stated (1968) that “serotonin has many functions but few have been sharply defined. The great variety of suggested roles can be said to be a tribute to man's ingenuity and his unquestionable willingness to write papers”. Since then, many more roles have been proposed for the involvement of 5-HT in functions of the central nervous system. Nevertheless, good evidence does exist that serotonin has some specific relationships to psychiatric disorders which are worth pursuing, in spite of great methodological difficulties.

Type
Research Article
Information
The British Journal of Psychiatry , Volume 153 , Issue S3: Progress in Antidepressant Therapy , September 1988 , pp. 26 - 39
Copyright
Copyright © 1988 The Royal College of Psychiatrists 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Akimoto, H., Nakakuki, M. & Machiyama, Y. (1960) Clinical experiences with MAO inhibitors (a comparison with Tofranil). Diseases of the Nervous System, 21, 645–647.Google Scholar
Alzheimer, O. (1960) Zur Pharmacotherapie depressiver Erkrankungen. Medizinische Welt, 37, 1918–1926.Google Scholar
Amat Aguirre, E. (1966) Tratamiento de las depresiones atipicas. Revue d'Information Médcale-Therapie, 41, 387–392.Google Scholar
Ananth, J. & Van den Steen, N. (1977) Systematic studies in the treatment of obsessive-compulsive neurosis with tricyclic antidepressants. Current Therapeutic Research, 21, 495–501.Google Scholar
Ananth, J., Solyom, L., Solyom, C. & Sookman, D. (1975) Doxepin in the treatment of obsessive-compulsive neurosis. Psychosomatics, 16, 185–187.Google Scholar
Ananth, J., Solyom, L., Bryntwick, S. & Krishnappa, U. (1979) Clomipramine therapy for obsessive-compulsive neurosis. American Journal of Psychiatry, 135, 700–701.Google Scholar
Ananth, J., Pecknold, J., Van den Steen, N. & Engelsmann, F. (1981) Double-blind comparative study of clomipramine and amitriptyline in obsessive neurosis. Progress in Neuro-Psychopharmacology, 5, 257–262.Google Scholar
Annesley, P. T. (1969) Nardil response in a chronic obsessive compulsive. British Journal of Psychiatry, 115, 748.CrossRefGoogle Scholar
Asberg, M. & Bertilsson, L. (1979) Serotonin in depressive illness - studies of CSF 5-HIAA. In Neuropsychopharmacology (ed. Saletu, B.). Oxford: Pergamon Press.Google Scholar
Annesley, P. T., Träskman, L. & Thoren, P. (1976a) 5-HIAA in the cerebrospinal fluid - a biochemical suicide predictor? Archives of General Psychiatry, 33, 1193–1197.Google Scholar
Annesley, P. T., Thoren, P. & Träskman-Bendz, L. (1976b) Serotonin depression: a biochemical subgroup within the affective disorders? Science, 191, 478–480.Google Scholar
Annesley, P. T., Edman, G., Rydin, E., Schalling, D., Träskman-Bendz, L. & Wagner, A. (1984a) Biological correlates of suicidal behaviour. Clinical Neuropharmacology, 7 (Suppl. 1), 758–759.Google Scholar
Annesley, P. T., Bertilsson, L., Martensson, B., Scalia-Tomba, G. P., Thoren, P. & Tràskman-Bendz, L. (1984b) CSF monoamine metabolites in melancholia. Acta Psychiatrica Scandinavica, 69, 201–219.Google Scholar
Banki, C. M. (1977) Correlation between cerebrospinal fluid amine metabolites and psychosomatic activity in affective disorders. Journal of Neurochemistry, 28, 255–257.Google Scholar
Banki, C. M. & Arato, M. (1983) Amine metabolites and neuroendocrine responses related to depression and suicide. Journal of Affective Disorders, 5, 223–232.Google Scholar
Banki, C. M. & Molnar, G. (1981) Cerebrospinal fluid 5-hydroxy-indole-acetic acid as an index of central serotonergic processes. Psychiatric Research, 5, 23–32.CrossRefGoogle Scholar
Banki, C. M., Banki, C. M. & Vojnik, M. (1981a) Cerebrospinal fluid amine metabolites, tryptophan and clinical parameters in depression. Part 2: Psychopathological symptoms. Journal of Affective Disorders, 3, 91–99.Google Scholar
Banki, C. M., Banki, C. M. & Fekete, I. (1981b) Correlation of individual symptoms and other clinical variables with cerebrospinal fluid amine metabolites and tryptophan in depression. Archiv für Psychiatrie und Nervenkrankheiten, 229, 343–353.Google Scholar
Banki, C. M., Arato, M., Papp, Z. & Kurcz, M. (1984) Biochemical markers in suicidal patients. Journal of Affective Disorders, 6, 341–350.Google Scholar
Bauer, G. & Novak, H. (1969) Doxepin, ein neues Antidepressivum; Wirkungvergleich mit Amitriptylin. Arzneimittel-Forschung, 19, 1642–1646.Google Scholar
Birkmayer, W. & Linauer, W. (1970) Storungen des tyrosin und tryptophan-metabolismus bei Depressionen. Archiv für Psychiatrie und Nervenkrankheiten, 213, 377–387.CrossRefGoogle Scholar
Blankenburg, W. (1969) Ansatze zu einer Psychopathologie des “common sense”. Confinia Psychiatrica, 12, 144–163.Google ScholarPubMed
Boer, J. A. den & Westenberg, H. G. M. (1987) Panic disorder: serotonin function and anti-panic treatment. In Abstracts of the International Symposium on Depression, Anxiety and Aggression. Amsterdam.Google Scholar
Boucquey, J. & Boucquey, J. P. (1961) Traitment ambulatoire a l'imipramine de 50 cas de psychoneurosis. Revue Médicale de Louvain, 5, 126–142.Google Scholar
Brewerton, T., Mueller, E. & George, T. (1986) Blunted prolactin response to the serotonin agonist m-chlorophenylpiperazine (m-CPP) in bulimia. Abstracts of the 15th Congress of the CINP. San Juan, Puerto Rico.Google Scholar
Brown, G. L. & Goodwin, F. K. (1984) Diagnostic, clinical and personality characteristics of aggressive men with low 5-HIAA. Clinical Neuropharmacology, 7 (Suppl. 1), 407–408.Google Scholar
Brown, G. L., Goodwin, F. K. & Ballenger, J. C. et al (1978) Aggression in humans correlates with cerebrospinal fluid amine metabolites. Psychiatric Research, 1, 131–139.CrossRefGoogle Scholar
Brown, G. L., Ebert, M. H., Goyer, P. F., Jimerson, D. C., Klein, W. J., Bunney, W. E. & Goodwin, F. K. (1982) Aggression, suicide and serotonin: relationship to CSF amine metabolites. American Journal of Psychiatry, 139, 741–746.Google Scholar
Bulat, M. (1984) Some criteria for the study of biochemical processes in CNS by analysis of the cerebrospinal fluid (CSF). Clinical Neuropharmacology, 7 (Suppl. 1), 286–287.Google Scholar
Bunney, W. E. & Fawcett, J. A. (1965) Possibility of a biochemical test for suicidal potential. Archives of General Psychiatry, 13, 232–239.CrossRefGoogle ScholarPubMed
Campbell, M., Friedman, E. & Vine, de (1974) Blood serotonin in psychotic and brain damaged children. Journal of Autism and Childhood Schizophrenia, 4, 33–41.Google Scholar
Carles Egea, F. (1961) Observaciones sobre el tratamiento ambulatorio de los estados depresivos con G 22355 (Tofranil). Medicina Clinica (Barcelona), 36, 448–452.Google Scholar
Carlsson, A., Corrodi, H. Fuxe, K. & Hokfelt, T. (1969) Effects of some antidepressant drugs on the depletion of intraneuronal brain catecholamine stores caused by 4, a-dimethyl-meta-tyramine. European Journal of Pharmacology, 5, 367–373.Google Scholar
Carroll, B. J., Greden, J. F. & Feinberg, M. (1981) Suicide, neuroendocrine dysfunction and CSF 5-HIAA concentrations in depression. In Recent Advances in Neuropsychopharmacology (eds Angrist, B., Burrows, G., Lader, M., Lingjaerde, O., Sedwall, G. & Wheatley, D.). Oxford: Pergamon Press.Google Scholar
Cassano, G. G., Castrogiovanni, P. & Mauri, M. (1981) A multicenter controlled trial in phobic obsessive psychoneurosis. The effect of Chlorimipramine and its combinations with halo-peridol and diazepam. Progress in Neuropsychopharmacology, 5, 129–138.Google Scholar
Castilla Del Pino, C. (1978) Introducción a la Psiquiatria. 1. Problemas generales de Psico(pato)logia. Madrid: Alianza.Google Scholar
Chinchilla, A. (1983) La anorexia nerviosa como equivalente depresivo. Barcelona: Ferrer.Google Scholar
Coccaro, E. M., Siever, L. J., Klar, M., Rubinstein, R., Moskovitz, A. & Davis, K. L. (1986) 5-HT in affective and personality disorders. In Abstracts of the ACNP Congress. San Juan, Puerto Rico.Google Scholar
Coppen, A., Shaw, D. M. & Farrell, J. P. (1963) Potentiation of the antidepressive effect of a monoamino-oxidose inhibitor by tryptophan. The Lancet, i, 79–87.Google Scholar
Coryell, W. & Schlesser, M. A. (1981) Suicide and the dexamethasone suppression test in unipolar depression. American Journal of Psychiatry, 138, 1120–1121.Google Scholar
Cruz, M. de la & Sarro-Martin, A. (1959) Experiencias con un nuevo antidepresivo derivado del iminodibencilo. Medicina Clinica (Barcelona), 33, 122–125.Google Scholar
Davis, V. E., Brown, H., Huff, J. A. & Cashaw, J. L. (1967) The alteration of serotonin metabolism to 5-hydroxytryptophol by ethanol ingestion in man. Journal of Laboratory and Clinical Medicine, 69, 132.Google Scholar
Demisch, K., Demisch, L., Buchholz, G., Althiff, P., Rosak, C. & Magnet, W. (1985) Effect of Pirlindole on endocrine parameters in healthy man. In Psychiatry. The State of the Art (eds Pichot, P., Berner, P., Wolf, R. & Thay, K.) Vol. 3. New York: Plenum.Google Scholar
Earle, B. V. & Earle, A. M. (1960) Imipramine (Tofranil) in mental health clinic and private practice. Canadian Medical Association Journal, 83, 804–806.Google Scholar
Farid, B. T. (1986) Irritability and resistance in obsessional neuroses. Psychopathology, 19, 289–293.Google Scholar
Ferguson, J. M. (1986) Fluoxetine induced weight loss in normal weight non depressed subjects. American Journal of Psychiatry, 143, 1496.Google Scholar
Freed, A., Kerr, T. A. & Roth, M. (1972) The treatment of obsessional neurosis. British Journal of Psychiatry, 120, 590–591.CrossRefGoogle ScholarPubMed
Freyhan, F. A. (1979) The target symptoms for treatment of depressive illness revisited. Comprehensive Psychiatry, 20, 495–501.Google Scholar
Fontaine, R. & Chouinard, G. (1985) Fluoxetine in the treatment of obsessive compulsive disorder. Progress in Neuropsychopharmacology & Biological Psychiatry, 9, 605–608.CrossRefGoogle ScholarPubMed
Fontaine, R. & Chouinard, G. (1986) An open clinical trial of fluoxetine in the treatment of obsessive-compulsive disorder. Journal of Clinical Psychopharmacology, 6, 98–101.Google Scholar
Fusté, R., Martinez, , Pina, A. & Monne, J. (1986) Expresión psicoendocrina de la conducta suicida. Estudio psico-endocrinológico en dos grupos de pacientes suicidas. Actas Luso-Espanolas de Neurologia, Psiquiatria y Ciencias Afines, 14, 369–378.Google Scholar
Gattuso, S. & Coacturi, V. (1964) L'imipramine nella terapia della nevrosi ossessiva. Acta Neurologica (Napoli), 19, 424–431.Google Scholar
Gebsattel, V. E. von (1954) Prolegomena einer medizinischer Anthropologie. Berlin: Springer.Google Scholar
Geisler, A. & Schou, M. (1969) Lithium for obsessive neurosis. Nordisk Psykiatrisk Tidsskrift, 23, 493–495.Google Scholar
Geisler, A. & Schou, M. (1973) Lithium treatment of obsessive-compulsive neurosis. A double blind therapeutic trial with negative results. Forensic Psychiatry, 2, 90–94.Google Scholar
Geissmann, P. & Kammerer, T. (1964) L'imipramine dans la nevrose obsessionnelle. Etude de 30 cas. L'Encéphale, 53, 369–382.Google Scholar
Giannini, A. J., Malone, D. A. & Piotrowski, T. A. (1986a) The serotonin irritation syndrome - a new clinical entity? Journal of Clinical Psychiatry, 47, 22–25.Google Scholar
Giannini, A. J., Jones, B. T. & Loiselle, R. H. (1986b) Reversibility of serotonin irritation syndrome with atmospheric anions. Journal of Clinical Psychiatry, 47, 141–143.Google Scholar
Goodwin, F. K., Cowdry, R. W. & Webster, M. H. (1978) Predictors of drug response in the affective disorders: toward an integrated approach. In Psychopharmacology: A question of progress (eds Lipton, M. A., DiMascio, A. & Killam, K. E.), pp. 1277–1288. New York: Raven Press.Google Scholar
Gorelick, D. A. (1986) Effect of fluoxetine on alcohol consumption. Alcoholism (NY), 10, 113.Google Scholar
Gottfries, G., Oreland, L., Wiberg, A. & Winblad, B. (1975) Lowered monoamine oxidase activity in brain from alcoholic suicides. Journal of Neurochemistry, 25, 667–673.Google Scholar
Griesinger, W. (1968) (reprint of the original edition, 1872) Gesammelte Abhandlungen. Amsterdam: E. J. Bonset.Google Scholar
Guyotat, J., Marin, A., Dubor, P. & Bonhomme, R. (1960) L'imipramine en dehors des états dépressifs. Journal Médical Lyon, 41, 367–375.Google Scholar
Heninger, G. R., Charney, D. S. & Sternberg, D. E. (1984) Serotonergic function in depressed patients and healthy subjects. Archives of General Psychiatry, 41, 398–402.CrossRefGoogle ScholarPubMed
Holsboer, F., Muller, O. A., Winter, K., Doerr, H. G. & Sippell, W. G. (1983) Effect of serotonin uptake inhibition by Zimelidine on hypothalamic- pituitary-adrenal activity. Psychopharmacology, 80, 85–87.CrossRefGoogle ScholarPubMed
Hsiao, J. K., Agren, H., Barkko, J. J., Rudofer, M. V. & Potter, W. Z. (1987) Monoamine neurotransmitter interactions and the prediction of antidepressant response. Archives of General Psychiatry, 44, 1078–1083.Google Scholar
Hudson, J. I., Pope, H. G. Jr., Jonas, J. M. & Yurgelun-Todd, D. (1983) Family history study of anorexia nervosa and bulimia. British Journal of Psychiatry, 142, 133–138.Google Scholar
Hughes, P. L., Wells, L. A., Cunningham, C. J. & Ilstrup, D. M. (1986) Treating bulimia with desipramine. Archives of General Psychiatry, 43, 182–186.Google Scholar
Hussain, M. Z. & Ahad, A. (1970) Treatment of obsessive-compulsive neurosis. Canadian Medical Association Journal, 103, 648–650.Google Scholar
Insel, T. (1982) Antiobsessional and antidepressant effects of clomipramine in the treatment of obsessive-compulsive disorder. Psychopharmacological Bulletin, 18, 115–117.Google Scholar
Insel, T. (1983) Obsessive-compulsive disorder. A double-blind trial of clomipramine and clorgyline. Archives of General Psychiatry, 40, 605–612.Google Scholar
Insel, T., Roy, B. F. & Cohen, R. M. (1982) Possible development of the serotonin syndrome in man. American Journal of Psychiatry, 139, 954–955.Google Scholar
Insel, T., Mueller, E. A. & Alterman, I. (1985) Obsessive-compulsive disorder and serotonin: is there a connection? Biological Psychiatry, 20, 1174–1188.Google Scholar
Irwin, M., Belendink, K., McCloskey, K. & Freedman, D. F. (1981) Tryptophan metabolism in children with attentional deficit disorders. American Journal of Psychiatry, 138, 1082–1085.Google Scholar
Isberg, R. S. (1981) A comparison of phenelzine and imipramine in an obsessive-compulsive patient. American Journal of Psychiatry, 138, 1250–1251.Google Scholar
Jacobsen, F. M., Sack, D. A., Wehr, T. A., Rogers, S. & Rosenthal, N. E. (1987) Neuroendocrine response to 5-hydroxi-tryptophan in seasonal affective disorder. Archives of General Psychiatry, 44, 1086–1091.Google Scholar
Jain, V. K., Swinson, R. P. & Thomas, J. G. (1970) Phenelzine in obsessional neurosis. British Journal of Psychiatry, 117, 237–238.CrossRefGoogle ScholarPubMed
Jaskari, M. (1980) Observations on mianserin in the treatment of obsessive neuroses. Current Medical Research Opinion, 6, (Suppl. 7), 128–131.CrossRefGoogle Scholar
Jenike, M. A. (1981) Rapid response of severe obsessive-compulsive disorder to tranylcypromine. American Journal of Psychiatry, 138, 1249–1251.Google Scholar
Jenike, M. A. (1982) Use of monoamine oxidase inhibitors in obsessive compulsive disorder. British Journal of Psychiatry, 140, 159.Google Scholar
Jimenez Garcia, P. (1967) Experiencia clinica con clomipramina en enfermos psiquiátricos. Libro de Becas Cursos, 58, 179–201.Google Scholar
Jouvet, M. (1969) Biogenic amines and the states of sleep. Science, 163, 32–41.CrossRefGoogle ScholarPubMed
Karabanow, O. (1977) Double blind controlled study in phobias and obsessions complicated by depression. International Journal of Medical Research, 5 (Suppl. 5), 42–48.Google Scholar
Kaye, W. H., Ebert, M. H., Raleigh, M. & Laker, R. (1984) Abnormalities in CNS monoamine metabolism in anorexia nervosa. Archives of General Psychiatry, 41, 350–355.Google Scholar
Kielholz, P. (1971) Diagnose und Therapie der Depressionen für den Praktiker. Munich: Lehmanns.Google Scholar
Kisker, K. P. (1969) Phenomenologie der Intersubtektivität. Handbuch der Psychologie. Vol. 7/1 Sozialpsychologie (ed. Granmann, ). Gottingen: Hofgrefe.Google Scholar
Kline, N., Wren, J. C., Cooper, T. B., Varga, E. & Canal, O. (1974) Evaluation of lithium therapy in chronic and periodic alcoholism. American Journal of Medical Science, 268, 15–22.Google Scholar
Korpi, E. R., Kleinman, J. E., Goodman, S. I., Phillipps, I., Delisi, L. E., Linnolia, M. & Wyatt, R. J. (1983) Serotonin and 5-hydroxyindoleacetic acid in brains of suicide victims. Comparison in chronic schizophrenic patients with suicide as a cause of death. Archives of General Psychiatry, 43, 594–600.CrossRefGoogle Scholar
Koyama, T. & Meltzer, H. Y. (1986) A biochemical and neuroendocrine study of the serotonergic system in depression. In New Results in Depression Research (ed. Hippius, H. et al). Berlin: Springer.Google Scholar
Kriger, G. (1974) The plasma level of cortisol as a predictor of suicide. Diseases of the Nervous System, 35, 237–240.Google Scholar
Krueger, A. P. & Reed, E. J. (1976) Biological impact of small air ions. Science, 93, 1209–1213.Google Scholar
Laakmann, G., Gugath, M., Kuss, H. T. & Zygan, (1984) Comparison of growth hormone and prolactin stimulation induced by clomipramine and desipramine in man in connection with clomipramine metabolism. Psychopharmacology, 82, 62–61.Google Scholar
Laboucarie, J., Rascol, A., Jorda, P., Guraud, R. & Leinadier, H. (1967) New prospects in the treatment of melancholic states. Therapeutic study of a major antidepressant, chlorimipramine. Revue Médicale de Toulouse, 3, 863–872.Google Scholar
Lancranjan, I., Wirz-Justice, A., Pühringer, W. & Del Pozo, E. (1976) Effect of 1-5-Hydroxytryptophan infusion on growth hormone and prolactin secretion. Clinical Endocrinology and Metabolism, 15, 588–593.Google Scholar
Langer, S. Z., Moret, R., Raisman, R., Dubocorich, M. L. & Briley, M. (1980) High affinity (3H)-imipramine binding in rat hypothalamus: association with uptake of serotonin but not of norepinephrine. Science, 210, 1133–1135.Google Scholar
Lesse, S. (1974) Masked Depression. New York: Aronson.Google Scholar
Levy, A. B., Kurtz, N. & Kling, A. S. (1984) Association between cerebral ventricular enlargement and suicide attempts in chronic schizophrenia. American Journal of Psychiatry, 141, 438–439.Google Scholar
Linnoila, M., Virkkunen, M., Scheinin, M., Muutila, A., Rimon, R. & Goodwin, F. K. (1984) Low cerebrospinal fluid 5-hydroxyindoleacetic acid concentration differentiates impulsive from nonimpulsive violent behaviour. Life Sciences, 33, 2609–2414.CrossRefGoogle Scholar
López-Ibor, J. J. (1950) La Anguistia Vital. Madrid: Paz Montalvo.Google Scholar
López-Ibor, J. J. (1966) Las Neurosis como Enfermedades del Animo Madrid: Gredos.Google Scholar
López-Ibor, J. J. & Lopez-Ibor, J. J. Jr (1975) Selection criteria for patients who should undergo psychiatric surgery. In Neurosurgical Treatments in Psychiatry, Pain, and Epilepsy (eds Sweet, W. H., Obrador, S. & Martin, J. G.) pp. 151–162. Baltimore: University Park Press.Google Scholar
López-Ibor, J. J. Jr (1969) Intravenous perfusions of monochlor-imipramine: technique and results. In The Present Status of Psychotropic Drugs (eds Cerletti, A. & Bové, F. J.). Amsterdam: Excerpta Medica.Google Scholar
López-Ibor, J. J. Jr (1972) Los equivalentes depresivos. Madrid: Paz Montalvo.Google Scholar
López-Ibor, J. J. Jr (1976) Depresive Aequivalente und maskierte Depressionen. In Psychiatrie und Psychosomatik (eds Spiegelberg, U., Michaelis, R. & López-Ibor, J. J.). Basel: Karger.Google Scholar
López-Ibor, J. J. Jr (1979) Why do depressions become masked? In Biological Psychiatry Today (eds Obiols, J., Ballus, C., González-Monclús, E. & Pujol, J.). Amsterdam: Elsevier North-Holland.Google Scholar
López-Ibor, J. J. Jr (1982) Fármacos antidepresivos. In Psiquiatria (eds López-Ibor, J. J. Jr, Ruiz Ogara, C. & Barcia, D.) Vol. II, pp. 1340–1378. Barcelona: Toray.Google Scholar
López-Ibor, J. J. Jr & Fernández-Cordoba, E. (1967) La monoclorimipramina en enfermos resistentes a otros tratamientos. Actas Luso-Españolas de Neurologia y Psiquiatria, 26, 119–147.Google Scholar
López-Ibor, J. J. Jr, Saiz-Ruiz, J. & Pérez de los Cobos, J. C. (1985) Biological correlations of suicide and aggressivity in major depressions (with melancholia): 5-hydroxyindoleacetic acid and cortisol in cerebral spinal fluid, dexamethasone suppression test and therapeutic response to 5-hydroxytryptophan. Neuropsychobiology, 14, 67–74.Google Scholar
López-Ibor, J. J. Jr, Saiz-Ruiz, J. & Moral, L. (1988) The fenfluramine challenge test as an index of severity of the affective disorders. Pharmacopsychiatry, 21, 9–14.Google Scholar
Maas, J. W., Fawcett, J. A. & Dekirmenjian, H. (1972) Catecholamine metabolism, depressive illness and drug response. Archives of General Psychiatry, 26, 252–262.Google Scholar
Manchanda, R., Sethi, B. B. & Gupta, S. C. (1979) Hostility and guilt in obsessive-compulsive neurosis. British Journal of Psychiatry, 135, 52–54.Google Scholar
Mann, J. J., Stanley, M., McBride, P. A. & McEwen, B. S. (1986) Increased serotonin2 and β-adrenergic receptor binding in the frontal corticols of suicide victims. Archives of General Psychiatry, 43, 954–959.Google Scholar
Mantegazzinni, P. (1960) Pharmacological actions of indole-alkylamins and precursors amino acids on the central nervous system. Handbuch der experimentelle Pharmacologie Vol. 19, p. 424. Berlin: Springer.Google Scholar
Marks, I. M., Stern, R. S., Mawson, D., Cobb, J. & McDonald, R. (1980) Clomipramine and exposure for obsessive-compulsive rituals. British Journal of Psychiatry, 136, 1–25.Google Scholar
Marshall, W. K. (1971) Treatment of obsessional illness and phobic anxiety state with clomipramine. British Journal of Psychiatry, 119, 467–468.Google Scholar
Matigama, Y., Kuroiwa, S. & Naruse, H. (1959) Some clinical experience with a new iminodibenzyl derivative G.22344 (Tofranil) (Japan). Bulletin of the Seishin-Igaku Institute (Clinical Psychiatry), 1, 581–585.Google Scholar
Mavissakalian, M., Turner, S. M., Michelson, L. & Jacob, R. (1985) Tricyclic antidepressants in obsessive-compulsive disorder: antiobsessional or antidepressant agents? II. American Journal of Psychiatry, 142, 572–576.Google Scholar
Meltzer, H. Y., Umberkoman-Wita, B., Robertson, A., Tricou, B. J., Lowy, M. & Perline, R. (1984) Effect of 5-hydroxytryptophan on serum cortisol levels in major affective disorders. I: Enhanced response in depression and mania. Archives of General Psychiatry, 41, 366–374.Google Scholar
Michaux, L., Duche, D. & Perpinoitis, (1961) Etude pharmaco-dynamique, clinique et therapeutique du G22344 en pedopsychiatrie. Proceedings of the 3rd World Congress of Psychiatry, Montreal, Vol. 2, pp. 927–929. Montreal: McGill University Press.Google Scholar
Moir, A. T. B. & Eccleston, B. (1968) The effects of precursor loading in the cerebral metabolism of 5-hydroxyindoles. Journal of Neurochemistry, 15, 1093–1108.Google Scholar
Montgomery, S. A. & Montgomery, D. B. (1982a) Pharmacological prevention of suicidal behaviour. Journal of Affective Disorders, 4, 291–298.Google Scholar
Montgomery, S. A. & Montgomery, D. B. (1982b) Drug treatment of suicidal behaviour. In Typical and atypical antidepressants: clinical practice (eds Costa, E. & Racagni, G.) pp. 347–355. New York: Raven Press.Google Scholar
Montgomery, S. A., McAuley, R., Ranni, S. J., Roy, D. & Montgomery, D. B. (1981) A double blind comparison of zimelidine and amitryptiline in endogenous depression. Acta Psychiatrica Scandinavica, 63, (Suppl. 290), 314–327.Google Scholar
Naviau, J., Ruyffelaere, J. & Lehembre, C. (1966) A propos de deux cas de nevrose obsessionnelle. Annales Médico-Psychologiques (Paris), 124, 254–258.Google Scholar
Ninan, P. T., Van Kamen, D. P., Cheinin, M., Linnoila, M., Bunney, W. E. & Goodwin, F. K. (1984) CSF 5-hydroxyindoleacetic acid levels in suicidal schizophrenic patients. American Journal of Psychiatry, 141, 566–569.Google Scholar
Oreland, L., Wiberg, A., Åsberg, M., Träskman, L., Sjostrand, L., Thoren, P., Bertilsson, L. & Tybring, G. (1981) Platelet MAO activity and monoamine metabolism in CSF in depressed and suicidal patients and in healthy controls. Psychiatric Research, 4, 21–29.CrossRefGoogle ScholarPubMed
Page, I. H. (1968) Serotonin. Chicago: Yearbook Medical Publishers.Google Scholar
Parati, E. A., Zarnadi, P., Cocchi, D., Caraceni, T. & Müller, E. E. (1987) Neuroendocrine effects of Quipazine in man in healthy state or with neurological disorders. Journal of Neurological Transmission, 47, 273–297.Google Scholar
Pare, C. M. B., Sandler, M. & Staley, R. S. (1957) 5-hydroxytryptamine deficiency in phenylketonuria. The Lancet, i, 1099.Google Scholar
Perry, G. K., Marshall, E. F., Blessed, G., Tomlinson, B. E. & Perry, R. H. (1983) Decreased imipramine binding in the brains of patients with depressive illness. British Journal of Psychiatry, 142, 188–192.Google Scholar
Pfeiffer, C. C. & Bacchi, D. (1975) Copper, zinc, manganese, niacin, and pyridoxine in the schizophrenias. Journal of Applied Nutrition, 27, 9–39.Google Scholar
Price, L. H., Goodman, W. K., Charney, D. S., Rasmussen, S. A. & Heninger, G. R. (1987) Treatment of severe obsessive-compulsive disorder with fluvoxamine. American Journal of Psychiatry, 144, 1059–1061.Google Scholar
Rabavilas, A. D., Boulougouris, J. C., Perissaki, C. & Stefanis, C. (1979) The effect of peripheral beta-blockade on psychophysiologic responses in obsessional neurotics. Comprehensive Psychiatry, 20, 378–383.Google Scholar
Redmond, D. E. Jr., Katz, M. M., Maas, J. W., Casper, R. & Davis, J. M. (1986) Cerebrospinal fluid amine metabolites. Relationships with behavioral managements in depressed, manic, and healthy control subjects. Archives of General Psychiatry, 939, 947.Google Scholar
Reid, D. T., Wong, D. T. & Threlkeld, P. G. (1986) Reduction of food intake with daily administration of a selective inhibitor of serotonic uptake, fluoxetine. Feeding Proceedings, 45, 609.Google Scholar
Renynghe de Voxrie, G. V. (1968) L'Anafranil dans l'obsession. Acta Neurologica Belgica, 68, 787–792.Google Scholar
Resnik, H. L. P. (1980) Suicide. In Comprehensive Textbook of Psychiatry (eds Kaplan, H. I., Freedman, A. F., Sadock, B. J.) Vol. II, pp. 2086–2098. Baltimore: Williams & Wilkins.Google Scholar
Rosner, F., Ong, B. H., Paine, R. S. & Mahanand, D. (1965) Blood-serotonin activity in trisomic and translocation Down's syndrome. The Lancet, i, 1191.CrossRefGoogle Scholar
Rydin, E., Schalling, D. & Åsberg, M. (1982) Rorschach ratings in depressed and suicidal patients with low CSF 5-HIAA. Psychiatric Research, 7, 229–243.Google Scholar
Schildkraut, J. J. (1965) The catecholamine hypothesis of affective disorders: a review of supporting evidence. American Journal of Psychiatry, 122, 509–522.Google Scholar
Schneider, K. (1950) Klinische Psychopathologie. Stuttgart: Thieme.Google Scholar
Sicuteri, F. (1959) Prophylactic and therapeutic properties of 1-methyl-lysergic acid etanolamide in migraine. Archives of Allergy, 15, 300.Google Scholar
Siever, L. J., Murphy, D. L., Slater, S., de la Vega, E. & Lipper, S. (1984) Plasma prolactin changes following fenfluramine in depressed patients compared to controls: an evaluation of central serotonergic responsivity in depression. Life Sciences, 34, 1029–1039.Google Scholar
Snyder, S. (1980) Amitriptyline treatment of obsessive-compulsive neurosis. Journal of Clinical Psychiatry, 41, 286–289.Google Scholar
Solyom, L. & Sookman, D. (1977) A comparison of clomipramine hydrochloride (Anafranil) and behavioural therapy in the treatment of obsessive neurosis. Journal of International Medical Research, 5 (Suppl. 5), 49–61.Google Scholar
Stanley, M. & Gershon, V. J. (1982) Tritiated imipramine binding sites are decreased in the frontal cortex of suicides. Science, 216, 1337–1339.Google Scholar
Stanley, M. & Mann, J. J. (1983) Serotonin-2 binding sites are increased in the frontal cortex of suicide victims. The Lancet, i, 214–216.Google Scholar
Stern, R. S. & Cobb, J. P. (1978) Phenomenology of obsessive-compulsive neurosis. British Journal of Psychiatry, 132, 233–239.Google Scholar
Stoff, D. M., Pollock, L., Vitiello, B., Berhar, D. & Bridger, W. H. (1987) Reduction of (3H)-imipramine binding sites on platelets of conduct-disordered children. Neuropsychopharmacology, 1, 55–62.Google Scholar
Strauss, H. (1959) Office treatment of depressive states with a new drug (imipramine). New York State Journal of Medicine, 59, 2906–2910.Google Scholar
Takahasi, S., Kondo, H., Yoshimura, H., Ochi, Y. & Yoshimi, U. (1973) Growth hormone response to administration of 1-5-hydroxytryptophan (5-HTp) in manic-depressive psychosis. Folia Psychiatrica et Neurologica Japanica, 27, 197.Google Scholar
Targum, S. D., Rosen, L. & Capodanno, A. E. (1983) The dexamethasone suppression test in suicidal patients with unipolar depression. American Journal of Psychiatry, 140, 877–879.Google Scholar
Tellenbach, H. (1963) Ueber die Behandlung phobischer und arankastischer Zustaende mit Smiptamin. Nevelarzt, 34, 133–138.Google Scholar
Thoren, P., Asberg, M. & Cronholm, B. (1980a) Clomipramine treatment of obsessive-compulsive disorder: a controlled clinical trial. Archives of General Psychiatry, 37, 1281–1289.Google Scholar
Thoren, P., Asberg, M. & Bertilsson, L. (1980b) Clomipramine treatment of obsessive compulsive disorder. II Biochemical aspects. Archives of General Psychiatry, 37, 1289–1294.Google Scholar
Thoren, P., Asberg, M., Cronholm, B., Jorenstedt, L. & Traskman, L. (1980c) Clomipramine treatment of obsessive-compulsive disorder: a controlled clinical trial. Archives of General Psychiatry, 37, 1281–1289.Google Scholar
Träskman, L., Tybring, G., Åsberg, M., Bertilsson, L., Lanto, O. & Sschalling, D. (1980) Cortisol in the CSF of depressed and suicidal patients. Archives of General Psychiatry, 37, 761–766.Google Scholar
Turner, S. M., Hersen, M., Bellack, A. S., Andrasik, F. & Capparell, H. V. (1980) Behavioural and pharmacological treatment of obsessive-compulsive disorders. Journal of Nervous and Mental Diseases, 168, 651–657.Google Scholar
Turner, S. M., Jacob, R. G. & Beidel, D. C. (1985) Fluoxetine treatment of obsessive-compulsive disorder. Journal of Clinical Psychopharmacology, 17, 61–62.Google Scholar
Van Praag, H. M. (1983) CSF 5-HIAA and suicide in non depressed schizophrenics. The Lancet, ii, 977–978.Google Scholar
Van Praag, H. M. (1986) Central serotonin via the neuroendocrine window. In American Psychiatric Association 1986 CME Syllabus. Washington: American Psychiatric Association Press.Google Scholar
Van Praag, H. M., Korf, J. & Puite, (1970) 5-HIAA levels in the cerebrospinal fluid of depressed patients treated with probenenid. Nature, 225, 1259–1260.Google Scholar
Van Praag, H. M., Flentge, F. & Korf, J. et al (1973) The influence of probenecid on the metabolism of serotonin, dopamine and their precursors in man. Psychopharmacology, 33, 141–151.Google Scholar
Vidal, G. & Vidal, B. (1963) Imipramine et obsessions. l'Encéphale, 52, 167–180.Google Scholar
Visitini, F. (1959) Terapia degli stati depressivi con Tofranil. Giornale Psychiatrico e Neuropatologico, 30, 3–8.Google Scholar
Walker, V. J. (1973) Explanation in obsessional neurosis. British Journal of Psychiatry, 123, 675–680.Google Scholar
Walter, H. K., Ebert, M. H., Gwirtsman, H. E. & Weiss, S. R. (1984) Differences in brain serotonergic metabolism between nonbulimic and bulimic patients with anorexia nervosa. American Journal of Psychiatry, 1598-1601.Google Scholar
Waxman, D. (1975) An investigation into the use of Anafranil in phobic and obsessional disorders. Scottish Medical Journal, 20, 61–66.Google Scholar
Waxman, D. (1973) A general practice investigation on the use of clomipramine in obsessional and phobic disorders. Journal of International Medical Research, 1, 417–420.Google Scholar
Wender, P. H. (1969) Platelet serotonin levels in children with ‘minimal brain dysfunction'. The Lancet, ii, 1021.Google Scholar
Wong, D. T. & Reid, L. R. (1986) Suppression of food intake in meal-fed and 2-deoxyglucose treated rats by enantiomers of fluoxetine and other inhibitors of monoamine uptake. Federal Proceedings, 45, 609.Google Scholar
Yaryura-Tobias, J. A. & Bhagawan, H. N. (1977) L-tryptophan in obsessive-compulsive disorders. American Journal of Psychiatry, 134, 1298–1299.Google Scholar
Yaryura-Tobias, J. A., Neziroglu, F. & Bergman, L. (1976) Clomipramine for obsessive neurosis: an organic approach. Current Therapeutic-Research, 20, 541–547.Google Scholar
Submit a response

eLetters

No eLetters have been published for this article.